Celtarys is a newly created company focused on the development of innovative chemical tools that improve the efficiency of the High Throughput Screening (HTS) process in early drug discovery:


Our proprietary technology allows the synthesis of fluorescent ligands with excellent performance features in terms of affinity, potency and selectivity that can be used in a variety of biological assays, from competitive binding assays to microscopy or kinetic studies.


Our patented proprietary technology is based on the scientific work of the research group of Prof. Eddy Sotelo, which combines a long-tracked expertise in medicinal chemistry & chemical biology with a deep knowledge of GPCR structure.

We count also with the expertise in pharmacology and HTS of the group of Prof. Mabel Loza, a worldwide leader in early drug discovery collaborative projects with pharma companies.

Celtarys has a multidisciplinary and balanced team with different profiles that provide expert knowledge in each area necessary to develop and market novel products, designed from the real unmet needs in the complex early drug discovery scenario.


Our Collaborators

Celtarys Research collaborates with several academic research groups and companies expert in drug discovery research.

Celtarys is part of the world’s largest AI-powered marketplace for medical research.



Celtarys Research has been selected and funded under the Proof-of-Concept Ignicia Program of the Galician Agency for Innovation, GAIN